Angiotech partner announces implantation of millionth TAXUS(R) Express2(TM) coronary stent system
19 Januar 2005 - 2:05PM
PR Newswire (US)
Angiotech partner announces implantation of millionth TAXUS(R)
Express2(TM) coronary stent system Market-leading product surpasses
major milestone VANCOUVER, Jan. 19 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:ANP)
corporate partner, Boston Scientific ("Boston"), today announced
the implantation of its millionth TAXUS(R) Express2(TM)
paclitaxel-eluting coronary stent system, marking a major milestone
for Boston Scientific and for the treatment of coronary artery
disease. "The implantation of our millionth TAXUS stent system is a
significant symbolic achievement for Boston Scientific," said Jim
Tobin, President and Chief Executive Officer of Boston Scientific.
"We are gratified that the TAXUS system has become the preferred
treatment option for clinicians, but more important, we are pleased
that so many patients have benefited from this innovative,
life-enhancing technology." "This is a noteworthy milestone for
Boston Scientific, for physicians and for patients," said Gregg
Stone, M.D., Director of Cardiovascular Research and Education,
Center for Interventional Vascular Therapy, Columbia University
Medical Center, New York. "This product has truly revolutionized
how we treat coronary artery disease and dramatically advanced the
practice of interventional cardiology." "We congratulate Boston
Scientific on this major milestone of the millionth TAXUS stent
implanted," said William Hunter, MD, MSc, President and Chief
Executive Officer of Boston Scientific. "We believe the TAXUS and
Liberte stents have set the standard for drug delivery in the
coronary arteries and we look forward to furthering this proof of
concept technology into other medical fields." The TAXUS stent
system received CE Mark in Europe in January 2003 and U.S. Food and
Drug Administration approval in March 2004. The TAXUS stent system
is the global market leader. Earlier this week, Boston announced
that it had launched its TAXUS(R) Liberte(TM) paclitaxel-eluting
stent system in 18 countries. The TAXUS Liberte system features
Boston's next-generation Liberte coronary stent. Boston plans to
launch the TAXUS Liberte system in Europe later this year and in
the United States next year, subject to regulatory approval. Boston
acquired worldwide exclusive rights from Angiotech to use
paclitaxel to coat its coronary stent products and has co-exclusive
rights to other vascular and non-vascular products. Vancouver-based
Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company
focusing on drug-coated medical devices and biomaterials, is
dedicated to enhancing the performance of medical devices and
biomaterials through the innovative uses of pharmacotherapeutics.
To find out more about Angiotech Pharmaceuticals, Inc., please
visit our website at http://www.angiotech.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," "may" and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. CONTACTS: Todd
Young, Angiotech Pharmaceuticals (Analysts & Investors), (604)
221-7676 ext 6933 Rui Avelar, Angiotech Pharmaceuticals, Inc.
(Analysts), (604) 221-7676 ext 6996 Eric Starkman, Starkman &
Associates (Media), (212) 252-8545 ext 12 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Todd Young, Angiotech
Pharmaceuticals (Analysts & Investors), (604) 221-7676 ext
6933; Rui Avelar, Angiotech Pharmaceuticals, Inc. (Analysts), (604)
221-7676 ext 6996; Eric Starkman, Starkman & Associates
(Media), (212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Okt 2023 bis Okt 2024